939986-15-9

Basic information

• Product Name: 4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36
• Synonyms: 4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36;4-[(3-Nitro-2-pyridinyl)amino]-1-piperidinecarboxylic acid tert-butyl ester;tert-Butyl 4-(3-nitropyridine-2-ylamino)piperidine-1-carboxylate
• CAS NO: 939986-15-9
• Molecular Formula: C15H22N4O4
• Molecular Weight: 322.35958
• Mol File: 939986-15-9.mol

Chemical Properties

• Appearance: /
• Density: 1.265
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36(939986-15-9)
• EPA Substance Registry System: 4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36(939986-15-9)

Safety Data

• Hazardous Substances Data: 939986-15-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36 is used as a building block in organic synthesis for the preparation of various pharmaceuticals and biologically active compounds. Its unique structure and functional groups make it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36 serves as an intermediate for the development of new drugs and therapeutic agents. Its presence in the molecular structure can contribute to the desired pharmacological properties and improve the efficacy of the final drug product.
Used as a Reference Standard in Analytical Testing:
4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36 is utilized as a reference standard in analytical testing due to its high purity. It helps in the accurate determination of the purity and composition of other related compounds in various industries, ensuring the quality and consistency of the final products.
Used in Research Applications:
4-(3-Nitro-pyridin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H22N4O4, MW: 322.36 is also employed in research applications, where it can be used to study the structure-activity relationships of various biologically active compounds. Its unique structure allows researchers to investigate the effects of different functional groups and modifications on the biological activity and pharmacological properties of the compound.

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 1480-87-1 2-fluoro-3-nitropyridine 

Downstream Products

• 1071154-76-1 tert-butyl 4-((3-aminopyridin-2-yl)amino)piperidine-1-carboxylate 
• 1185316-09-9 (3-nitropyridin-2-yl)-piperidin-4-yl-amine hydrochloride 

Relevant articles and documents

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

IMIDAZOPYRIDINONE COMPOUND

The present invention aims to provide a novel compound which has prolyl hydroxylase (PHDs) inhibitory effect and which is useful for the treatment of inflammatory bowel diseases such as ulcerative colitis and the like. The present invention relates to a imidazopyridinone compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. The compounds of the present invention or pharmaceutically acceptable salts thereof which have prolyl hydroxylase inhibitory effect and, are useful as agents for the treatment of inflammatory bowel diseases such as ulcerative colitis and the like. In an embodiment, the present invention relates to a method for treating an inflammatory bowel disease

METHOD FOR PRODUCING IMIDAZOPYRIDINONE COMPOUND

PROBLEM TO BE SOLVED: To provide a novel production method of an imidazopyridinone compound useful as a treatment agent for inflammatory bowel diseases (IBDs). SOLUTION: The present disclosure provides a method for the synthesis of, for example, an imidazopyridinone compound shown below. The method includes a process of introducing a desired substituent into the 1st-position of 2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine, having an N-protected 3-pyrrolidino group at the 3rd-position; then deprotecting a 3rd-position substituent; and further introducing a desired substituent into N of the pyrrolidino group. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

PHARMACEUTICAL COMPOSITION CONTAINING IMIDAZOPYRIDINONE COMPOUND

PROBLEM TO BE SOLVED: To provide a compound useful as a treatment agent for inflammatory bowel diseases such as ulcerative colitis, and a pharmaceutical composition containing the same. SOLUTION: The present disclosure provides a pharmaceutical composition containing an imidazopyridinone compound of the following formula (I) or a pharmacologically acceptable salt thereof. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

TRPA1 MODULATORS

This disclosure relates to polycyclic heteroaromatic compounds useful as TRPA1 modulators, as well as compositions and methods of treating pain that include the compounds.

COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof.

HETEROBICYCLIC COMPOUNDS

Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

AZABENZIMIDAZOLONES

Compounds are provided having the general structure of formula I: In formula I, one member of the group (W, X, Y and Z) is a nitrogen atom and the remaining three members of the group are each independently a carbon atom covalently bonded to a radical, R4. The radicals, R1 R2, R3 and R4 are each defined herein, and n is an integer from 1 to 4. Also provided are stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, salt hydrates, acid salt hydrates, and polymorphs of the compounds having the structure of formula I. The compounds bind the prostaglandin D2 receptor and are useful in the prophylaxis and treatment of prostaglandin D2-mediated diseases and conditions, including pain and inflammation, as well as asthma and allergic diseases and conditions.

2,4-Diaminopyridine δ-opioid receptor agonists and their associated hERG pharmacology

A number of libraries were produced to explore the potential of 2,4-diaminopyridine lead 1. The resulting diaminopyridines proved to be potent and selective δ-opioid receptor agonists. Several rounds of lead optimisation using library chemistry identified compound 17 which went on to show efficacy in an electromyography model of neuropathic pain. The structure-activity relationship of the series against the hERG ion channel proved to be a key selectivity hurdle for the series.